Related Experiment Video
Updated: Jun 3, 2026
07:10
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
Proteasome inhibition improves diaphragm function in an animal model for COPD
Hieronymus van Hees1, Coen Ottenheijm, Leo Ennen
1Department of Pulmonary Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. h.vanhees@long.umcn.nl
Summary
Proteasome inhibitors, like Bortezomib, can improve diaphragm function in animal models of chronic obstructive pulmonary disease (COPD). This treatment restores myosin concentration, addressing diaphragm weakness linked to COPD.
Area of Science:
- Biomedical research
- Respiratory medicine
- Muscle physiology
Background:
- Diaphragm muscle weakness is a significant problem in chronic obstructive pulmonary disease (COPD), increasing patient morbidity and mortality.
- Increased proteasome-mediated contractile protein degradation is a key factor contributing to diaphragm weakness in COPD patients.
Purpose of the Study:
- To investigate the impact of proteasome inhibition on diaphragm function and contractile protein levels.
- To evaluate Bortezomib's efficacy in an established animal model of COPD-induced diaphragm dysfunction.
Main Methods:
- Utilized an elastase-induced emphysema hamster model to mimic COPD.
- Administered Bortezomib (proteasome inhibitor) or saline vehicle to assess effects on diaphragm-specific force, proteasome activity, and protein concentrations (myosin, actin).
Main Results:
- Emphysematous hamsters exhibited higher diaphragm proteasome activity and concentration, alongside a ~25% reduction in specific force-generating capacity and myosin concentration.
- Bortezomib treatment significantly reduced proteasome activity and notably improved diaphragm-specific force-generating capacity, fully restoring myosin levels in emphysematous hamsters.
Conclusions:
- Proteasome inhibition, specifically with Bortezomib, enhances diaphragm contractile function in a COPD animal model.
- Restoration of myosin concentration is the mechanism by which proteasome inhibitors improve diaphragm strength, suggesting the proteasome as a therapeutic target for COPD-related diaphragm weakness.
Related Concept Videos
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:23Chronic Obstructive Pulmonary Disease II: Emphysema
Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...